News coverage about Radius Health (NASDAQ:RDUS) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Radius Health earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.5029662940457 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Radius Health Presents Positive Data From ACTIVExtend BMD Responder Analysis – Nasdaq (nasdaq.com)
- Commit To Purchase Radius Health At $22.50, Earn 8.7 … – Nasdaq – Nasdaq (nasdaq.com)
- Zacks: Brokerages Anticipate Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million (americanbankingnews.com)
- Radius Health (RDUS) Presents At 38th Annual Cowen And Company Healthcare Conference – Slideshow (seekingalpha.com)
Several research firms have recently commented on RDUS. BidaskClub upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Morgan Stanley lifted their price objective on shares of Radius Health from $57.00 to $61.00 and gave the stock an “overweight” rating in a research note on Friday, March 2nd. ValuEngine upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup reiterated a “hold” rating and set a $43.00 price objective on shares of Radius Health in a research note on Monday, January 22nd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating for the company in a research note on Monday, February 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $52.22.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.16). The company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $7.37 million. Radius Health’s revenue for the quarter was up 666.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.22) EPS. equities analysts predict that Radius Health will post -5.05 earnings per share for the current year.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 75,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was bought at an average cost of $34.38 per share, for a total transaction of $2,578,500.00. Following the completion of the transaction, the insider now directly owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 80,000 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were acquired at an average price of $32.52 per share, with a total value of $2,601,600.00. Following the completion of the transaction, the insider now directly owns 5,853,799 shares of the company’s stock, valued at $190,365,543.48. The disclosure for this purchase can be found here. Insiders own 15.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/2018/03/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radius-health-rdus-stock-price/2006038.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.